Foghorn Therapeutics
Andrew Germain is a seasoned legal professional specializing in intellectual property, currently serving as Vice President of Legal at Foghorn Therapeutics Inc. since June 2020, after previously holding the position of Senior Director of Intellectual Property. Prior to this role, Andrew worked as a Patent Attorney and Patent Agent at Clark+Elbing LLP from January 2013 to June 2020 and was an Organic Synthesis Fellow in Medicinal Chemistry at the Broad Institute from July 2009 to January 2013. Andrew's academic background includes a Ph.D. in Chemistry from Boston University and a Bachelor of Arts in Chemistry from the College of the Holy Cross.
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.